Prior to this term at the U.S. Supreme Court, Jessica Ellsworth of Hogan Lovells had argued at federal appellate courts across the country, but never the High Court. This term that changed, as Ellsworth argued two SCOTUS cases, including representing Danco Laboratories, the maker of the abortion pill Mifepristone in the court’s first case tackling abortion-related issues since its Dobbs decision overturned Roe v. Wade.
In an unanimous decision earlier this month, the Supreme Court rejected a lawsuit challenging the way the Food and Drug Administration handled certain approvals for mifepristone, allowing the drug to stay on the market. The court found that the plaintiffs challenging the FDA’s actions—pro-life doctors and associations—lacked standing to sue based on their desire to make mifepristone “less available for others.”
